|1.||Strychor, Sandra: 5 articles (02/2012 - 12/2007)|
|2.||Zamboni, William C: 5 articles (02/2012 - 12/2007)|
|3.||Zamboni, Beth A: 5 articles (02/2012 - 12/2007)|
|4.||Seo, Sang-Soo: 4 articles (03/2012 - 06/2008)|
|5.||Bang, Yung-Jue: 4 articles (02/2012 - 01/2006)|
|6.||Kim, Chae-Yong: 3 articles (08/2013 - 06/2009)|
|7.||Kim, Seung-Ki: 3 articles (08/2013 - 06/2009)|
|8.||Cho, Byoung Chul: 3 articles (06/2013 - 10/2010)|
|9.||Kim, Se Kyu: 3 articles (06/2013 - 10/2010)|
|10.||Kim, Joo Hang: 3 articles (06/2013 - 10/2010)|
|1.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2008 - "This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). "
10/01/2013 - "The aim of this phase II study was to investigate the efficacy and toxicity of belotecan in previously untreated elderly patients with small cell lung cancer (SCLC). "
04/01/2012 - "The aim of this study was to evaluate the efficacy and safety of belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). "
04/01/2011 - "The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan as a second-line therapy in patients with small cell lung cancer (SCLC). "
06/01/2010 - "The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan in patients with small cell lung cancer (SCLC). "
02/01/2012 - "Covariate analysis revealed that tumor in the liver was a significant covariate for clearance of encapsulated CKD-602 and that age significantly influenced the release rate of CKD-602 from S-CKD602. "
12/01/2007 - "S-CKD602 provides pharmacokinetic advantages in plasma, tumor, and tumor ECF compared with nonliposomal CKD-602 at 1/30th of the dose, which is consistent with the improved antitumor efficacy of S-CKD602 in preclinical studies. "
01/01/2012 - "Plasma concentrations of encapsulated CKD-602 and monocytes counts from 45 patients with solid tumors were collected following intravenous administration of S-CKD602 in the phase I study. "
01/25/2003 - "The described method was used for the pharmacokinetic analysis of CKD-602 during clinical phase I studies, in patients with solid tumors."
01/01/2012 - "Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients."
|3.||Ovarian Neoplasms (Ovarian Cancer)
06/01/2008 - "To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. "
06/01/2010 - "Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer."
05/15/2011 - "Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer."
03/01/2012 - "The combined regimen of belotecan followed by oral etoposide showed promising activity in platinum-resistant or heavily pretreated ovarian cancer patients at the dose level of 50 mg of oral etoposide."
03/01/2012 - "Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer."
02/01/2012 - "In the present study, we evaluated the in vivo antitumor effect of CKD-602 in a mouse glioma model. "
06/01/2009 - "Thus, CKD-602 showed a significant anticancer effect on glioma cells in vitro and is a promising candidate for further studies on malignant gliomas."
02/01/2012 - "These results suggest that CKD-602 has a significant anticancer effect on glioma cells in vivo."
02/01/2012 - "Nude mice with established U87MG glioma were treated with a dose of CKD-602 of 0mg/kg (control group, injection with saline only; n=5), 40 mg/kg (group A) or 60 mg/kg (group B). "
02/01/2012 - "Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model."
01/01/2014 - "We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. "
01/01/2014 - "Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma."
05/01/2011 - "Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle in patients with recurrent or progressive cervical carcinoma who were unsuitable candidates for curative treatment with surgery or radiotherapy. "
05/01/2011 - "Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix."
05/01/2011 - "The Phase II trial was conducted to evaluate the efficacy and toxicity of belotecan (CKD 602), a topoisomerase I inhibitor, in persistent or recurrent carcinoma of the cervix. "
|2.||Type I DNA Topoisomerases (Topoisomerase I)
|7.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Infusion Pumps (Infusion Pump)
|3.||Heterologous Transplantation (Xenotransplantation)